| 0.2379 -0.003 (-1.25%) | 10-24 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 0.36 | 1-year : | 0.43 |
| Resists | First : | 0.31 | Second : | 0.36 |
| Pivot price | 0.27 |
|||
| Supports | First : | 0.22 | Second : | 0.18 |
| MAs | MA(5) : | 0.24 |
MA(20) : | 0.26 |
| MA(100) : | 0.29 |
MA(250) : | 1.31 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 8.7 |
D(3) : | 10.8 |
| RSI | RSI(14): 40.3 |
|||
| 52-week | High : | 3.4 | Low : | 0.18 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ INTS ] has closed above bottom band by 13.1%. Bollinger Bands are 25.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.25 - 0.25 | 0.25 - 0.25 |
| Low: | 0.23 - 0.23 | 0.23 - 0.23 |
| Close: | 0.24 - 0.24 | 0.24 - 0.24 |
Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer. The company was founded in 2012 and is headquartered in Westport, Connecticut.
Fri, 24 Oct 2025
Connecticut Biotech Firm Intensity Therapeutics Navigates Critical Reverse Stock Split - FinancialContent
Thu, 23 Oct 2025
Intensity Therapeutics Approves Reverse Stock Split Proposal - TipRanks
Wed, 10 Sep 2025
Intensity Therapeutics Reports INVINCIBLE-4, Presurgical Triple-Negative Breast Cancer Study Update - PR Newswire
Wed, 20 Aug 2025
Benchmark lowers Intensity Therapeutics stock price target to $1.50 on dilution - Investing.com
Thu, 07 Aug 2025
Intensity Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - PR Newswire
Mon, 04 Aug 2025
Biotech Intensity Therapeutics Secures $6.6M Funding at Premium Price, Extends Operations Through 2026 - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 49 (M) |
| Shares Float | 41 (M) |
| Held by Insiders | 12.7 (%) |
| Held by Institutions | 6.5 (%) |
| Shares Short | 866 (K) |
| Shares Short P.Month | 671 (K) |
| EPS | -0.82 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.07 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -122.7 % |
| Return on Equity (ttm) | -334.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -11 (M) |
| Levered Free Cash Flow | -6 (M) |
| PE Ratio | -0.3 |
| PEG Ratio | 0 |
| Price to Book value | 2.97 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.06 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|